TNF Inhibitor for Gastrointestinal Disease Treatment, EP3810095A1
Summary
The EPO published patent application EP3810095A1 for BT Bidco, Inc., covering a TNF inhibitor formulation for treating gastrointestinal diseases. The patent application was published under IPC classifications A61K 9/22, A61K 31/436, and A61K 48/00. The application designates all EU member states plus other EPC contracting states including CH, GB, LI, MC, NO, TR, and IS.
What changed
The EPO published patent application EP3810095A1 for BT Bidco, Inc., a TNF inhibitor composition for treating diseases of the gastrointestinal tract. The application claims priority from December 27, 2019 and is classified under A61K pharmaceutical preparation codes. The patent designates all EU member states as well as CH, GB, LI, MC, NO, IS, and TR.
For pharmaceutical companies developing or marketing TNF inhibitor therapies, this patent could represent a blocking patent in the European market for GI disease applications. Companies should review Freedom to Operate analyses for their existing or pipeline TNF inhibitor products in the designated territories. Inventors include Mitchell Lawrence Jones, Sharat Singh, Christopher Loren Wahl, Harry Stylli, Kevin David Howe, and Aruna Perera.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR
Publication EP3810095A1 Kind: A1 Apr 08, 2026
Applicants
BT Bidco, Inc.
Inventors
JONES, Mitchell Lawrence, SINGH, Sharat, WAHL, Christopher Loren, STYLLI, Harry, HOWE, Kevin David, PERERA, Aruna
IPC Classifications
A61K 9/22 20060101AFI20191227BHEP A61K 31/436 20060101ALI20191227BHEP A61K 48/00 20060101ALI20191227BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.